BXP — Beximco Pharmaceuticals Share News
0.000.00%
- £171.75m
- £237.96m
- BDT39.27bn
- 96
- 97
- 67
- 99
REG - Beximco Pharmaceut - Financial Results for the First Quarter
AnnouncementREG - Beximco Pharmaceut - Results for the 12-month period ended 30 June 2022
AnnouncementREG - Beximco Pharmaceut - Notification of Preliminary Results and AGM
AnnouncementREG - Beximco Pharmaceut - Q3 Financial Results
AnnouncementREG - Beximco Pharmaceut - Sanofi Bangladesh Ltd. renamed Synovia Pharma PLC
AnnouncementREG - Beximco Pharmaceut - MPP sub-license for Pfizer’s COVID-19 treatment
AnnouncementREG - Beximco Pharmaceut - Half Year Results 2021-22
AnnouncementREG - Beximco Pharmaceut - Payment of Cash Dividend
AnnouncementREG - Beximco Pharmaceut - License to produce molnupiravir for COVID-19
AnnouncementREG - Beximco Pharmaceut - World's first generic version of Pfizer’s Paxlovid
AnnouncementREG - Beximco Pharmaceut - Annual General Meeting Statement
AnnouncementREG - Beximco Pharmaceut - Delivery of COVID-19 vaccine doses
AnnouncementREG - Beximco Pharmaceut - Update on the supply of COVID-19 vaccine
AnnouncementREG - Beximco Pharmaceut - Statement re: media comment
AnnouncementREG - Beximco Pharmaceut - Notice of AGM
AnnouncementREG - Beximco Pharmaceut - Results for First Quarter Ended 30 September 2021
AnnouncementREG - Beximco Pharmaceut - Launch of world’s first generic molnupiravir
AnnouncementREG - Beximco Pharmaceut - Results for the year ended 30 June 2021
AnnouncementREG - Beximco Pharmaceut - Notification of Preliminary Results and AGM
Announcement